Although the routine use of these two growth factors in patients without infection is generally well tolerated, there are an increasing number of publications on respiratory deterioration with ARDS during G-CSF/GM-CSF–induced neutropenia recovery [83–87]. This evidence concerns the gene CSF3 and acute respiratory distress syndrome.